GlobeNewswire PharmaOriginal article
ANI Pharmaceuticals Announces Positive Six-Month Topline Data from the Phase 4 Open-Label, Single-Arm SYNCHRONICITY Trial Evaluating Fluocinolone Acetonide Intravitreal Implant in Patients with Chronic Non-Infectious Uveitis
Data ReadoutpositiveFluocinolone Acetonide Intravitreal ImplantPositive
AI Analysis
Summary
ANI Pharmaceuticals announced positive topline data from the Phase 4 SYNCHRONICITY trial of Fluocinolone Acetonide Intravitreal Implant in patients with chronic non-infectious uveitis affecting the posterior segment of the eye at six months.
Clinical Trial Data
Phase
4
Outcome Details
Positive six-month topline data from Phase 4 SYNCHRONICITY trial
Importance:6/10
Sentiment:
0.75
Phase 4positive dataophthalmologyuveitisintravitreal implant
Related Companies
Read the original article
Published by GlobeNewswire Pharma on July 13, 2026 10:50 AM